

**45.** The isolated polypeptide of claim 43, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

**46.** An isolated antibody that binds specifically to the isolated polypeptide of claim 43.

**47.** A recombinant host cell that expresses the isolated polypeptide of claim 43.

**48.** A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 47 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

**49.** The polypeptide produced by claim 48.

**50.** A method for preventing, treating, or ameliorating a hematopoietic or hematologic disorder, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 43.

**51.** A method of diagnosing a hematopoietic or hematologic disorder in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 33; and

(b) diagnosing the hematopoietic or hematologic disorder based on the presence or absence of said mutation.

**52.** A method of diagnosing a hematopoietic or hematologic disorder in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 43 in a biological sample; and

(b) diagnosing the hematopoietic or hematologic disorder based on the presence or amount of expression of the polypeptide.

**53.** A method for identifying a binding partner to the polypeptide of claim 43 comprising:

(a) contacting the polypeptide of claim 43 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

**54.** The gene corresponding to the cDNA sequence of SEQ ID NO:X.

**55.** A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

**56.** The product produced by the method of claim 53.

\* \* \* \* \*